JM6 structure
|
Common Name | JM6 | ||
---|---|---|---|---|
CAS Number | 1008119-83-2 | Molecular Weight | 518.60600 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C23H26N4O6S2 | Melting Point | N/A | |
MSDS | Chinese USA | Flash Point | N/A | |
Symbol |
GHS06 |
Signal Word | Danger |
Use of JM6JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC50 of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research[1]. |
Name | 3,4-Dimethoxy-N-[4-(3-nitrophenyl)-5-(1-piperidinylmethyl)-1,3-th iazol-2-yl]benzenesulfonamide |
---|---|
Synonym | More Synonyms |
Description | JM6 is a weak kynurenine 3-monooxygenase (KMO) inhibitor with an IC50 of 19.85 μM for mouse KMO. JM6 can be used for Alzheimer's diseases research[1]. |
---|---|
Related Catalog | |
Target |
IC50: 19.85 μM (kynurenine 3-monooxygenase)[1] |
References |
Molecular Formula | C23H26N4O6S2 |
---|---|
Molecular Weight | 518.60600 |
Exact Mass | 518.12900 |
PSA | 163.20000 |
LogP | 6.13710 |
Symbol |
GHS06 |
---|---|
Signal Word | Danger |
Hazard Statements | H301 |
Precautionary Statements | P301 + P310 |
RIDADR | UN 2811 6.1 / PGIII |
Pharmacological kynurenine 3-monooxygenase enzyme inhibition significantly reduces neuropathic pain in a rat model.
Neuropharmacology 102 , 80-91, (2016) Recent studies have highlighted the involvement of the kynurenine pathway in the pathology of neurodegenerative diseases, but the role of this system in neuropathic pain requires further extensive res... |
3,4-Dimethoxy-N-[4-(3-nitrophenyl)-5-(1-piperidinylmethyl)-2-thiazolyl]-benzenesulfonamide |
JM6 |